Once-weekly (OW) subcutaneous semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in Canada on 4 January 2018 for treating adults with type 2 diabetes (T2D) [1]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.